WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis

Rhinitis, Allergic, Perennial Clinical Trial

Official title:

Phase III Double-blind Comparative Study of WAL801CL Dry Syrup in Paediatric Perennial Allergic Rhinitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02182544
• Other study ID #: 262.258
• Status: Completed
• Phase: Phase 3
• First received: July 2, 2014
• Last updated: July 11, 2014
• Start date: June 2001

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

Study to investigate the efficacy of WAL801CL Dry Syrup in comparison with ketotifen fumarate on pediatric perennial allergic rhinitis and to evaluate the safety of WAL801CL Dry Syrup compared to ketotifen fumarate and to confirm the appropriateness of dosage of WAL801 Dry Syrup.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 151
• Est. primary completion date: December 2001
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 15 Years

Eligibility

Inclusion Criteria:

• 15 years of age or younger

• Body weight of 14 kg or more

• Typical symptoms of perennial allergic rhinitis, and within 2 or higher score of serum specific immunoglobulin E (IgE) caused by house dust (HD) or mite in the data obtained with the past one year

• "Moderate" or "Severe" in the Allergic Rhinitis Severity Classification during the observation period

• The Patient Diary can be entered by the patient or parent

• Outpatients

Exclusion Criteria:

• Absolute necessity of treatment with a drug that may affect the evaluation of the effect of the investigational drug (e.g., anti-histamines, anti-allergics, steroid, vasopressors). Patients being treated with the following drugs, however, may be included

• Intal® Oral or Inhalation

• Any eye drops other than Zaditen® Eye Drop

• External preparations (liniment, poultice)

• Initiation of desensitisation therapy within the past 6 months

• Onset of acute upper respiratory inflammation during the observation period

• Nasal disease, such as acute or chronic rhinitis, nasal polyp, hypertrophic rhinitis, septal deviation*, sinusitis*, and hypertrophied adenoid*, of such a degree that the disease affects evaluation of the effect of the test drug (*: X-ray examination will be conducted if necessary)

• That pollen (cider, ragweed, Japanese cypress, orchard grass, etc.) is a double antigen, and that the study will be conducted in the season of air-borne pollen, and symptoms may be exacerbated by pollen

• Present or past history of a convulsive disease, such as epilepsy (convulsion threshold values may be decreased by the comparator drug, ketotifen fumarate)

• Clinically significant abnormal changes in laboratory measurements, and thus judgement that the patient is ineligible for inclusion in this study; however, if the patient is judged as falling into Grade 2 or more according to the MHW (Ministry of health and welfare) Adverse Reaction Severity Classification Criteria, the patient will be excluded from the study

• Clinically significant renal, hepatic or cardiac disease, or other complications, and thus judgement that the patient is ineligible for inclusion in the study; however, if the patient is judged as falling into Grade 2 or more according to the MHW Adverse Reaction Severity Classification Criteria, the patient will be excluded from the study

• Past history of drug allergy

• 1 month, or 6 times as long as the half life of the investigational drug if it is over 1 month, will not have passed since participation in any other clinical trial study, at the time of the initiation of this study

• Judgement by the Principal Investigator or Investigator that the patient is ineligible for inclusion in this study

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Rhinitis
• Rhinitis, Allergic, Perennial

Intervention

Drug:
• WAL801CL dry syrup

• Ketotifen fumarate dry syrup

• Ketotifen fumarate dry syrup placebo

• WAL 801 CL dry syrup placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total severity scores of nasal symptoms judged by the physician		2 weeks of first administration of study drug	No
Secondary	Severity score for each nasal symptom given by the physician		2 weeks of first administration of study drug	No
Secondary	Nasal symptom score in the diary		2 weeks	No
Secondary	Total scores for nasal symptoms in the diary		2 weeks of first administration of study drug	No
Secondary	Severity score for allergic rhinitis according to the Allergic Rhinitis Severity Classification		2 weeks	No
Secondary	Impression of the patient or the parent		week 2 after first administration of study drug	No
Secondary	Occurrence of adverse events		up to 2 weeks after administration of study drug	No
Secondary	Number of patients with abnormal changes from baseline in laboratory tests (hematology, biochemistry, urinalysis)		Baseline and week 2	No

External Links

•   Link